↓ Skip to main content

Advances in Cancer Biomarkers

Overview of attention for book
Cover of 'Advances in Cancer Biomarkers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cancer Biomarkers: A Status Quo
  3. Altmetric Badge
    Chapter 2 Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives
  4. Altmetric Badge
    Chapter 3 Use of Biomarkers in Screening for Cancer.
  5. Altmetric Badge
    Chapter 4 The Role of Metabolomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools
  6. Altmetric Badge
    Chapter 5 The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools.
  7. Altmetric Badge
    Chapter 6 Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development
  8. Altmetric Badge
    Chapter 7 Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects
  9. Altmetric Badge
    Chapter 8 The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects
  10. Altmetric Badge
    Chapter 9 Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
  11. Altmetric Badge
    Chapter 10 Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
  12. Altmetric Badge
    Chapter 11 The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
  13. Altmetric Badge
    Chapter 12 Advances in Cancer Biomarkers
  14. Altmetric Badge
    Chapter 13 Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer
  15. Altmetric Badge
    Chapter 14 The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects
  16. Altmetric Badge
    Chapter 15 CA 19-9: Biochemical and Clinical Aspects.
  17. Altmetric Badge
    Chapter 16 Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
  18. Altmetric Badge
    Chapter 17 Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects
  19. Altmetric Badge
    Chapter 18 Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
  20. Altmetric Badge
    Chapter 19 A Critical Approach to Clinical Biochemistry of Chromogranin A.
  21. Altmetric Badge
    Chapter 20 The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer
  22. Altmetric Badge
    Chapter 21 The Role of CTCs as Tumor Biomarkers
Attention for Chapter 10: Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
Altmetric Badge

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
Chapter number 10
Book title
Advances in Cancer Biomarkers
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-94-017-7215-0_10
Pubmed ID
Book ISBNs
978-9-40-177214-3, 978-9-40-177215-0
Authors

McMahon, Brandon J, Kwaan, Hau C, Brandon J. McMahon, Hau C. Kwaan

Abstract

Members of the plasminogen-plasmin (PP) system participate in many physiologic functions. In particular, uPA, its receptor (uPAR) and its inhibitor PAI-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion and metastasis as well as angiogenesis and fibrosis. Thus, quantification of uPA, uPAR and PAI-1 in tumors and, in some cases in the circulating blood, became of potential value in the prognostication of many types of cancer. These include cancer of the breast, stomach, colon and rectum, esophagus, pancreas, glioma, lung, kidney, prostate, uterine cervix, ovary, liver and bone. Published data are reviewed in this chapter. Clinical validation of the prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these can be overcome. Hopefully the use of these biomarkers will be applied to other types of cancer in the near future.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 17%
Student > Bachelor 5 14%
Student > Master 5 14%
Student > Ph. D. Student 5 14%
Student > Postgraduate 3 8%
Other 2 6%
Unknown 10 28%
Readers by discipline Count As %
Medicine and Dentistry 15 42%
Agricultural and Biological Sciences 4 11%
Biochemistry, Genetics and Molecular Biology 2 6%
Business, Management and Accounting 1 3%
Neuroscience 1 3%
Other 1 3%
Unknown 12 33%